Aptevo Therapeutics

APVO

Market cap $22.1M

SEATTLE, WASHINGTON / ACCESS Newswire / October 8, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific and trispecific immuno-oncology therapeutics, today announced its participation in upcoming key financial, industry, scientific and medical conferences this fall, providing the opportunity to highlight continued momentum and recent developments among a broad range of stakeholder audiences. These conferences include: 4th Annual ROTH Healthcare Opportunities Conference October 9, 2025 - Metropolitan Club, New York City, New York Aptevo will participate in a panel on Acute Myeloid Leukemia titled "Novel AML Therapies Showing Clear Clinical Progress," discussing progress and recent trial outcomes of its lead asset, mipletamig, and sharing emerging evidence of its differentiated clinical profile in frontline AML-where strong safety, tolerability, and early efficacy continue to demonstrate meaningful potential for improved patient outcomes Biotechnology Innovation Organization (BIO)-Europe 2025 - 31st Annual International Partnering Conference November 3-5, 2025 (in-person); Digital Partnering Days: November 11-12, 2025 - Messe Wien Exhibition & Congress Center, Vienna, Austria The Business Development Team will be on-site and actively participating in meetings at the largest biotechnology meeting in Europe Society of Immunotherapy in Cancer (SITC) 2025 - 40th Anniversary Annual Meeting November 5-9, 2025 - Gaylord National Resort & Convention Center, National Harbor, Maryland Aptevo's R&D Team will present a poster highlighting a novel trispecific targeting Nectin-4, CD3 and CD40 to overcome the immunosuppressive the tumor microenvironment American Society of Hematology (ASH) 2025 - 67th American Society of Hematology Annual Meeting & Exposition December 6-9, 2025 - Orange County Convention Center, Orlando, Florida Interim results from the ongoing Phase 1b/2 RAINIER trial evaluating mipletamig in frontline combination therapy for the treatment of AML, will be presented in a poster session by the clinical team.

Aptevo Therapeutics (NASDAQ:APVO) saw its shares jump sharply after the company reported encouraging clinical data from its Phase 1b/2 RAINIER trial evaluating mipletamig, a first-in-class CD123 x CD3 bispecific antibody, in patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. Aptevo said that Cohort 3 of the trial achieved a 100% remission rate, with 40% of patients reaching minimal residual disease (MRD)-negative status, a key indicator linked to improved long-term outcomes.

No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolerability Trial progressing efficiently, Cohort 4 open for enrollment SEATTLE, WA / ACCESS Newswire / September 16, 2025 / Aptevo Therapeutics ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company developing novel bispecific and trispecific immuno-oncology therapeutics, today announced a 100% remission rate in Cohort 3 of its Phase 1b/2 RAINIER trial evaluating mipletamig, the Company's first-in-class CD123 x CD3 bispecific antibody, in combination with venetoclax + azacitidine for newly diagnosed patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy. Aptevo also reported that no dose-limiting toxicities or cytokine release syndrome have been observed in the RAINIER trial, or among any frontline patients treated with mipletamig to date.

New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppressive cells Mipletamig-driven clinical validation of the CRIS-7-derived CD3 binding domain underpins Aptevo's introduction of new, trispecific CD3-directed anti-cancer molecules SEATTLE, WASHINGTON / ACCESS Newswire / September 4, 2025 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTMand ADAPTIR-FLEXTM platform technologies, today announced expansion of its anti-cancer pipeline with the filing of two provisional patents for trispecific candidates, APVO452 and APVO451 for prostate cancer and multiple, additional solid tumor types with significant unmet needs. These programs build on the Company's growing suite of CRIS-7-derived, CD3-directed molecules and are supported by compelling clinical validation from lead candidate, mipletamig, which has demonstrated strong clinical safety and efficacy for the treatment of acute myeloid leukemia (AML).

Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer. Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3 portfolio targeting both hematologic and solid tumors SEATTLE, WA / ACCESS Newswire / August 13, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today reinforced the strategic importance of its preclinical asset APVO442-an investigational CD3-engaging bispecific antibody designed to treat prostate cancer.

Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types CD3 bispecific portfolio now includes three candidates - mipletamig (AML), APVO442 (prostate cancer), and newly added APVO455 - advancing a targeted, tumor-specific strategy uniquely engineered for safety, tumor specificity and clinical impact Mipletamig, continues to outperform benchmarks, trial enrollment continues $15.9 million raised in 2Q25, extending cash runway into late 4Q25 SEATTLE, WASHINGTON / ACCESS Newswire / August 11, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology Company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today reported financial results for the quarter ended June 30, 2025, and provided a business update. Second Quarter Highlights Pipeline Expansion - Introduced APVO455, a Nectin-4 x CD3 bispecific for solid tumors, expanding the Company's suite of differentiated CRIS-7-derived CD3 - engaging molecules in development, including lead candidate, mipletamig Mipletamig for acute myeloid leukemia (AML) - Achieved 85% remission* rate (11/13 patients) in frontline AML patients across two trials in combination therapy Increased Liquidity - Completed financings that raised a total of $15.9 million, extending cash runway into late 4Q25 Secured an equity line of credit for up to an additional $25 million in capital *Remission = complete remission (CR) and, complete remission with blood markers that have not yet recovered (CRi).

SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 2,465,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 12,325,000 shares of its common stock (the "Common Warrants") at a purchase price of $3.25 per share and associated Common Warrants in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with five Common Warrants, each to purchase one share of common stock.

Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumors New candidate APVO455 targets Nectin-4+ cancers, joins mipletamig (AML) and APVO442 (prostate) in Aptevo's tumor-directed CD3 suite SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced the addition of preclinical candidate APVO455 to its growing portfolio of CD3-directed candidates built on the CRIS-7 derived CD3 binding domain-an approach demonstrating compelling potential across both hematologic and solid tumors. With this announcement, Aptevo now has a suite of three CD3-engaging molecules in development.

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Friday.

Aptevo Therapeutics shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia study.